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Benzoyl-protected hydroxylamines for improved chemical 
synthesis of oligonucleotides containing nitroxide spin labels 
 
Haraldur Y. Juliusson‡,[a] Anna-Lena J. Segler‡[a] and Snorri Th. Sigurdsson*[a] 
‡These authors contributed equally to this work 
Abstract: Oligonucleotides containing nitroxide spin labels, used in 
biophysical studies of nucleic acids, are frequently prepared by 
chemical synthesis. However, during the synthesis of spin-labeled 
oligonucleotides, the nitroxides are partially reduced to the 
corresponding amines. Here we report that a benzoylated 
hydroxylamine can be used as a protected form of the nitroxide to 
avoid this reduction. The benzoyl group is stable through the 
oligonucleotide synthesis and is readily removed under standard 
oligonucleotide deprotection conditions, yielding a hydroxylamine that 
is oxidized in situ to the nitroxide. This method was used to 
incorporate the rigid spin labels Ç and Çm into DNA and RNA 
oligonucleotides, respectively, including a doubly-labeled 36-
nucleotide long DNAzyme. Enzymatic digestion of the spin-labeled 
oligonucleotides and subsequent HPLC analysis showed that the 
nitroxides were intact. This protecting group strategy facilitates high-
yielding synthesis of spin-labeled DNA and RNA oligonucleotides 
using the phosphoramidite method. 
Introduction 
Nucleic acids are essential for life as they contain the cellular 
blue-print in living organisms and are active participants in the 
cellular machinery, for example in regulation of gene 
expression.[1]  Therefore, it is of great interest to determine their 
structure and dynamics in order to gain insights into their function. 
Several different techniques are used for such studies. X-ray 
crystallography can provide three-dimensional structures and 
precise arrangements of atoms in space, but growing a highly-
diffractive single crystal can be a laborious and time-consuming 
task.[2] Moreover, the crystals of the biomolecules might not 
represent their biologically active conformation.[3] Nuclear 
magnetic resonance (NMR) spectroscopy provides high-
resolution structural information under biologically relevant 
conditions as well as information on dynamics.[4] However, NMR 
has inherently low sensitivity and, therefore, a relatively large 
amount of sample is required and the measurements can be time-
consuming.[5] Förster resonance energy transfer (FRET) is a  
technique that measures the distances between two or more 
chromophores.[6] FRET has been used extensively to study 
tertiary structures of nucleic acids and has enabled studies of 
single molecules.[7] 
Electron paramagnetic resonance (EPR) spectroscopy is another 
method to study the structure and dynamics of nucleic acids.  For 
structural studies, continuous wave (CW) EPR can be used to 
measure distances up to 25 Å.[8] Pulsed dipolar spectroscopy, 
such as pulsed electron-electron double resonance (PELDOR), 
also called double electron-electron resonance (DEER), 
relaxation induced dipolar modulation enhancement (RIDME), 
single frequency technique for refocusing dipolar couplings 
(SIFTER) and double quantum coherence (DQC) can be used to 
measure distances between 15-160 Å.[9] Information about 
dynamics of nucleic acids can be obtained directly from line-
broadening of CW-EPR spectra[10] and from orientation studies 
using pulsed EPR.[11] In EPR spectroscopy, transitions between 
spin states of unpaired electrons in a magnetic field are measured. 
Since nucleic acids and most other biomolecules are diamagnetic, 
a paramagnetic center needs to be introduced.  Paramagnetic 
metal ions have been used as spin labels for EPR[12] but more 
often organic radicals, such as nitroxides, are employed for spin 
labeling.[13] 
Incorporation of spin labels at specific sites in nucleic acids is 
called site-directed spin-labeling (SDSL) and is performed either 
through covalent or noncovalent binding.[14] Covalent spin-
labeling is either carried out post-synthetically or by using spin-
labeled phosphoramidites as building blocks in chemical 
synthesis of nucleic acids.[14a, 14b, 14d] Post-synthetic labeling 
requires oligonucleotides that have reactive groups at specific 
sites for modification with the spin label after the oligonucleotide 
synthesis.[14a, 14b, 14d]  An advantage of post-synthetic labeling is 
that the label is not exposed to the reagents used for 
oligonucleotide synthesis, but drawbacks include non-specific 
reactions with other functional groups present in nucleic acids and 
incomplete spin labeling. Also, the spin labels that are 
incorporated post-synthetically contain flexible tethers, that 
render distance measurements less accurate and relative 
orientation of labels cannot be determined.[15]  
With the phosphoramidite method, it is possible to incorporate 
intricate labels with unique structural features, such as rigid labels, 
into nucleic acids.[16] Drawbacks of the phosphoramidite approach 
include the synthetic effort required to prepare spin-labeled 
phosphoramidites and exposure of the nitroxides to reagents 
used in the solid-phase synthesis, resulting in a partial[17] or even 
complete[18] reduction of the nitroxide to its corresponding amine. 
For oligonucleotides shorter than ca. 15-nucleotide (nt) long, the 
desired spin-labeled product can be readily separated from the 
reduced material by denaturing polyacrylamide gel 
electrophoresis (DPAGE). For longer oligonucleotides, on the 
other hand, the separation is usually a tedious and non-trivial task 
that often results in a mixture of spin labeled and reduced material. 
Protecting the nitroxide with a group that is stable through the 
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oligonucleotide synthesis would eliminate this drawback of spin-
labeling nucleic acids by the phosphoramidite method. 
Nitroxides have been protected as O-methyl hydroxylamines 
under reaction conditions that would otherwise reduce the 
nitroxide.[19] The methyl group can be removed by treatment with 
meta-chloroperbenzoic acid (m-CPBA), but this reagent can also 
oxidize nitrogen atoms in the heterocyclic nucleobases present in 
nucleic acids.The tert-butyldimethylsilyl (TBDMS) group has been 
used to protect the hydroxyl amine of 2,2,6,6-tetramethylpiperidyl-
1-oxyl (TEMPO) for the synthesis of a nitroxide-nitroxide 
biradical,[20] however, less than 50% of the nitroxide was 
recovered after removal of the TBDMS groups. Photolabile 
protecting groups have been used to protect TEMPO during 
oligonucleotide synthesis, of both DNA and RNA; irradiation with 
light gave high yields of spin-labeled oligonucleotides.[21] 
Photoprotection of nitroxides is a useful method for photocaging, 
allowing a controlled release of the protecting group in functional 
nucleic acids.[22] However, additional synthetic effort is required to 
prepare and incorporate the photolabile protecting group and 
specialized equipment is needed to irradiate the oligomers with 
the right wavelength for deprotection.  An ideal protecting group 
for routine preparation of spin-labeled oligonucleotides would be 
removed by using standard oligonucleotide deprotecting 
conditions, returning the radical without having to include an 
additional deprotection step. An acetyl group has been used to 
protect a TEMPO moiety attached to a deoxyuridine 
phosphoramidite during incorporation into DNA. After oligomer 
deprotection using standard conditions,[23] complete removal of 
the acetyl group required additional incubation with aqueous 
NaOH (0.5 M), conditions that are not compatible with RNA. 
During the course of this work, we also became aware of a report 
describing the incorporation of 2-N-tert-butylaminoxyl-2’-
deoxyadenosine into DNA, utilizing acetylated hydroxylamine,[24] 
however, the structure of this nitroxide is very different from the 
nitroxides that are normally used for spin labeling.  
Here we describe a protecting group strategy for chemical 
synthesis of nitroxide-labeled DNA and RNA that is based on 
protection of the corresponding hydroxyl amine with a benzoyl 
group, which is compatible with the conditions of solid-phase 
synthesis of oligonucleotides. The benzoyl group is quantitatively 
removed under standard conditions used for oligonucleotide 
deprotection, yielding a hydroxylamine that oxidizes in situ to the 
corresponding nitroxide radical.[21a, 25] This method was used to 
synthesize fully spin-labeled DNA and RNA oligonucleotides in 
high yields. 
 
Results and Discussion 
The main incentive for carrying out this work was to enable 
incorporation of rigid spin labels into long sequences (>15 nt) by 
solid-phase synthesis, but such spin labels cannot be 
incorporated by post-synthetic labeling. Specifically, we were 
interested in incorporating the spin labels Ç[16] and Çm[26] (Figure 
1) into DNA and RNA oligonucleotides, respectively. These spin 
labels are valuable probes of both structure and dynamics of 
nucleic acids.[16, 26] An advantage of using these labels for 
developing a general nitroxide protecting group strategy is that 
reduction of the nitroxides yields the fluorescent amines Çf[16] and 
Çmf[27] (Figure 1), allowing for easy detection. 
The synthesis of Ç-Bz and Çm-Bz (Scheme 1) began by 
protecting the 5’- and 3’- hydroxyl groups of Ç and Çm with 
TBDMS. The resulting nitroxide radicals 1 and 2 were reduced 
with ascorbic acid to yield the corresponding hydroxylamines that  
 
Figure 1. The rigid spin labels Ç[16] and Çm[26] and their corresponding amines 
Çf[16] and Çmf.[27] 
were subsequently benzoylated, followed by removal of the 
TBDMS groups to give Ç-Bz and Çm-Bz. The benzoyl protecting 
group was shown to be stable under all reaction conditions used 
for oligonucleotide synthesis for more than five days, except when 
exposed to either 5-ethylthio tetrazole or 5-benzylthio tetrazole, 
present in the activation solutions, where slight removal of the 
benzoyl group was observed after 24 h (data not shown). 
The benzoyl protecting group was readily removed within one and 
two hours under deprotecting conditions for RNA (MeNH2:NH3 in 
H2O/EtOH) and DNA (satd. aq. NH3), respectively. The 5’-
hydroxyl groups of Ç-Bz and Çm-Bz (Scheme 1) were protected 
as 4,4’-dimethoxytrityl (DMT) ethers and subsequently 
phosphitylated to give phosphoramidites 3 and 4, respectively, in 
good yields. 
Phosphoramidite 4 was used to synthesize an 8-nt long, spin-
labeled RNA oligomer (I, Table 1). This oligomer was chosen 
because short oligonucleotides that contain a reduced spin label 
Table 1. Spin-labeled DNA and RNA oligonucleotides synthesized by solid-
phase synthesis. Oligonucleotides II* and VI* were synthesized with the 
phosphoramidite of unprotected nitroxide spin-labels Çm[26] and Ç,[16] 














can be separated by DPAGE from oligomers containing the 
nitroxide, thus allowing direct visualization of both products. An 
RNA of the same sequence was also synthesized with a 
phosphoramidite of the unprotected Çm[26] (II, Table 1) for 
comparison. 
 
Scheme 1. Synthesis of Ç-Bz and Çm-Bz and their corresponding 
phosphoramidites. a. Imidazole, tert-butyldimethylsilyl chloride (TBDMSCl), 
DMF, pyridine. b. L-Ascorbic acid, 1,4-dioxane, H2O, c. Benzoyl chloride (BzCl), 
Et3N. d. tert-Butyl ammonium fluoride (TBAF), THF. e. 4,4’-Dimethoxytrityl 
chloride (DMTCl), 4-dimethylaminopyridine (DMAP), pyridine. f. 2-Cyanoethyl-
N,N,N’,N’-tetraisopropylphosphorodiamidite, diisopropylammonium tetrazolide 
(DIBAT), CH2Cl2. 
The phosphoramidite containing the protected spin label coupled 
well during the solid-phase synthesis as indicated by a strong 
orange color of the trityl cation that appears during removal of the 
DMT group. Figure 2A shows a denaturing polyacrylamide gel of 
crude RNA I (lane 1) and RNA II (lane 2). No fluorescent band 
was detected for RNA I (Figure 2A, lane 1), synthesized with Çm-
Bz. In contrast, RNA II (Figure 2A, lane 2), synthesized with the 
unprotected Çm, contained a strong fluorescent byproduct, which 
indicated partial reduction of the nitroxide to the corresponding 
Çmf. 
For further analysis, crude RNAs I and II were digested with snake 
venom phosphodiesterase, nuclease P1 and calf spleen alkaline 
phosphatase, and the digest was analyzed by HPLC (Figure 
3).[16] The HPLC chromatogram for RNA I (Figure 3A) contained 
five peaks, one for each natural nucleoside and a strongly 
retained nucleoside that was shown by co-injection to be Çm, 
while RNA II (Figure 3B) showed a peak for both Çm and Çmf 
along with the natural unmodified nucleosides. 
 
Figure 2. Analysis of spin-labeled oligonucleotides by DPAGE. A. Crude 8-mer 
RNA oligonucleotides I (lane 1) and II (lane 2) (5’-UGCAUÇmUU-3’), 
synthesized using 4 and the phosphoramidite of unprotected Çm,[26] 
respectively. B. Crude 21-mer DNA oligonucleotides IV (lane 1) and V (lane 2) 
(5’-d(PHO-TGAGGTAGTAGGTTGTATAÇT)-3’), synthesized using 3 and the 
phosphoramidite of unprotected Ç,[16] respectively. PHO is a phosphate. 
Phosphoramidite 4 was also used to synthesize a 21-nt long RNA 
(III, Table 1), which was enzymatically digested and analyzed by 
HPLC (Figure 3C). In this case, a small peak (<5%) can be seen 
for Çmf, along with Çm and the natural nucleosides.  These 
results show that the benzoyl protecting group on Çm was stable 
during the oligonucleotide synthesis and was completely removed 
during the deprotection, giving high yields of spin-labeled RNA. 
 
Figure 3. HPLC chromatograms of RNA oligonucleotides after enzymatic 
digestion with snake venom phosphodiesterase, nuclease P1 and alkaline 
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Crude RNA II (5’-UGCAUÇmUU-3’) synthesized using the phosphoramidite of 
unprotected Çm.[26] C.  RNA III (5’-AGAUGCGCGÇmGCGCGACUGAC-3’) 
synthesized using 4. 
In an analogous manner to the RNA synthesis, phosphoramidite 
3 and a phosphoramidite of Ç that does not contain the benzoyl 
protecting group were used to synthesize two 21-mer DNA 
oligonucleotides of the same sequence, (IV and V, Table 1). Here 
the spin-label was placed close to the 3’-end, which increases the 
exposure of the label to the chemicals used in each cycle of the 
oligonucleotide synthesis. Figure 2B shows DPAGE analysis of 
crude DNA IV (Figure 2B, lane 1) and crude DNA V (Figure 2B, 
lane 2). No fluorescent band was detected for DNA IV while DNA 
V showed a strong fluorescent band that overlapped with the band 
of the spin-labeled oligonucleotide. 
 
Figure 4. HPLC chromatograms of DNA oligonucleotides after enzymatic 
digestion with snake venom phosphodiesterase, nuclease P1 and alkaline 
phosphatase. A. Crude DNA IV (5’-d(PHO-TGAGGTAGTAGGTTGTATAÇT)-
3’) synthesized using 3. B. Crude DNA V (5’-d(PHO-TGAGGTAGTAGGTT 
GTATAÇT)-3’) synthesized using the phosphoramidite of unprotected Ç.[16] C.  
DNAzyme VI (5’-d(TGTAAÇGCACTACCAGCGGCTGGAAATCTÇTCTCGT)-
3’) synthesized using 3. PHO is a phosphate. 
These crude DNA samples were digested and analyzed by HPLC 
(Figure 4). While the digest of oligomer IV (Figure 4A) showed 
the natural nucleosides and Ç, the digest of oligomer V contained 
a very small peak for Ç along with some strongly retained 
impurities (Figure 4B). The quality of the synthesis of spin labeled 
DNA was also reflected in the yields of purified material obtained 
from a 1 µmol synthesis, that gave 180 and 11 nmols of oligomers 
VI and V, respectively. Moreover, the small amount of oligo V 
obtained after repeated purifications gave a ca. 50/50 mixture of 
oligonucleotides containing Ç and Çf. To demonstrate the use of 
this method for the synthesis of a longer oligonucleotide, a 36-nt 
DNAzyme (VI, Table 1) containing Ç at two positions (6 and 31) 
was prepared. No fluorescent bands were detected upon 
purification of the oligonucleotide by DPAGE. Enzymatic digestion 
followed by HPLC analysis showed four peaks for the natural 
nucleosides and a peak for Ç (Figure 4C) in the ratios expected 
for a fully spin-labeled oligonucleotide. 
 
Conclusions 
The nitroxide functional groups of Ç and Çm were protected by 
benzoylation of the corresponding hydroxylamines. The resulting 
Ç-Bz and Çm-Bz were converted into phosphoramidites and 
used for oligonucleotide synthesis of DNA and RNA of various 
lengths. The benzoyl protecting group was stable through the 
chemical synthesis of the oligonucleotides and was readily 
removed by standard oligonucleotide deprotection conditions to 
give nitroxide-labeled oligonucleotides; enzymatic digestion and 
HPLC analysis was used to quantify the spin label in the samples. 
These results show that this protecting group strategy for 
nitroxides can be used as a general method to prepare spin-
labeled nucleic acids using the phosphoramidite approach. 
Experimental Section 
General materials and methods. All commercially available 
reagents were purchased from Sigma-Aldrich, Inc. or Acros 
Organics and used without further purification. 2’-Deoxyuridine 
and 2’-O-methyluridine were purchased from Rasayan Inc. USA. 
CH2Cl2, pyridine and CH3CN were dried over calcium hydride and 
freshly distilled before use. All moisture- and air-sensitive 
reactions were carried out in oven-dried glassware under an inert 
atmosphere of Ar. Thin-layer chromatography (TLC) was 
performed using glass plates pre-coated with silica gel (0.25 mm, 
F-25, Silicycle) and compounds were visualized under UV light 
and by p-anisaldehyde staining. Column chromatography was 
performed using 230–400 mesh silica gel (Silicycle). For acid 
sensitive compounds the silica gel was basified by passing 3% 
Et3N in CH2Cl2 through the column before use. 1H-, 13C- and 31P-
NMR spectra were recorded with a Bruker Avance 400 MHz 
spectrometer. Commercial grade CDCl3 was passed over basic 
alumina shortly before dissolving tritylated nucleosides for NMR 
analysis. Chemical shifts (δ) are reported in parts per million 
(ppm) relative to the partially deuterated NMR solvent CDCl3 (7.26 






ppm for 1H NMR and 77.16 ppm for 13C). 31P-NMR chemical shifts 
are reported relative to 85% H3PO4 as an external standard. All 
coupling constants were measured in Hertz (Hz). Nitroxide 
radicals show broadening and loss of NMR signals due to their 
paramagnetic nature and therefore, those NMR spectra are not 
shown. Mass spectrometric analyses of all organic compounds 
were performed on an ESI-HRMS (Bruker, MicrOTOF-Q) in a 
positive ion mode. 
TBDMS-Ç (1). To a solution of Ç[16] (130 mg, 0.30 mmol) in DMF 
(3 mL) and pyridine (3 mL) were added imidazole (62 mg, 0.91 
mmol) and TBDMSCl (137 mg, 0.91 mmol) and the resulting 
solution was stirred at 22 °C for 24 h. H2O (50 mL) was added and 
the organic phase was extracted with EtOAc (3 x 10 mL). The 
combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by flash column 
chromatography using a gradient elution (MeOH:CH2Cl2, 0:100 to 
10:90), to yield 1 (160 mg, 95%) as a yellow solid. HRMS (ESI): 
m/z calcd for C33H53N4O6Si2+Na+: 680.3401 [M+Na]+; found 
680.3396. 
TBDMS-Ç-Bz (5). To a solution of 1 (53 mg, 0.08 mmol) in 1,4-
dioxane (3.5 mL) was added L-ascorbic acid (72 mg, 0.41 mmol) 
in H2O (1 mL) and the reaction mixture stirred at 40 °C for 30 min. 
H2O (3.5 mL) and CH2Cl2 (5 mL) were added and the mixture was 
stirred for 5 min. The organic phase was separated and used 
directly in the next step by passing it through a plug of Na2SO4 
under an inert atmosphere of Ar, into a solution of BzCl (46 μl, 
0.41 mmol) and Et3N (23 μL, 0.16 mmol) in CH2Cl2 (2 mL). The 
reaction was stirred at 22 °C for 30 min, the solvent removed in 
vacuo and the residue purified by flash column chromatography 
using a gradient elution (MeOH:CH2Cl2, 0:100 to 10:90), to yield 
5 (55 mg, 95%) as a yellow solid. 1H NMR (400 MHz, CDCl3): δ = 
8.10-8.03 (m, 2H), 7.53 (d, J = 7.4 Hz, 1H), 7.40-7.44 (m, 3H), 
7.19 (s, 1H), 6.34 (s, 1H), 6.22 (t, J = 6.1 Hz, 1H), 4.40 – 4.24 (m, 
1H), 3.84 (dt, J = 8.6, 2.9 Hz, 2H), 3.76 – 3.66 (m, 1H), 2.36 – 
2.22 (m, 1H), 2.26-2.32 (m, 1H), 2.06 – 1.90 (m, 1H), 1.42 (d, J = 
10.1 Hz, 12H), 0.90 (s, 9H), 0.81 (s, 9H), 0.09 (d, J = 8.8 Hz, 6H), 
0.00 ppm (s, 6H); 13C NMR (101 MHz, CDCl3): δ = 166.13, 160.85, 
142.58, 140.14, 139.53, 133.08, 129.62, 128.54, 127.76, 121.42, 
112.27, 108.11, 100.88, 87.59, 85.80, 71.24, 68.60, 67.27, 66.52, 
62.49, 41.78, 26.06, 25.71, 18.49, 17.95,-4.55 -4.85, -5.46 ppm; 
HRMS (ESI): m/z calcd for C40H58N4O7Si2+Na+: 785.3742 
[M+Na]+; found 785.3736. 
Ç-Bz. To a solution of 5 (118 mg, 0.16 mmol) in THF (3 mL) was 
added TBAF (0.5 mL, 0.50 mmol, 1.0 M in THF) at 0 °C and the 
reaction mixture was stirred at 0 °C for 8 h. The solvent was 
removed in vacuo and the residue purified by flash column 
chromatography using a gradient elution (MeOH:CH2Cl2, 0:100 to 
25:75), to yield Ç-Bz (67 mg, 81%) as a yellow solid. 1H NMR (400 
MHz, CDCl3): δ = 8.09 (d, J = 7.3 Hz, 2H), 7.70 – 7.62 (m, 2H), 
7.55 (t, J = 7.7 Hz, 2H), 6.66 (s, 2H), 6.23 (t, J = 6.4 Hz, 1H), 4.39 
(dt, J = 6.6, 3.5 Hz, 1H), 3.94 (m, J = 3.1 Hz, 1H), 3.81-3.73 (m, 
2H), 2.34 (ddd, J = 13.5, 6.0, 3.7 Hz, 1H), 2.17 (dt, J = 13.4, 6.5 
Hz, 1H), 1.47 ppm (s, 12H); 13C NMR (101 MHz, CDCl3): δ = 170.9, 
146.8, 143.8, 143.0, 137.4, 133.1, 132.5, 112.7, 91.5, 90.1, 74.6, 
72.4, 65.2, 62.1, 62.1, 44.3, 31.7, 27.4, 23.3, 16.5 ppm; HRMS 
(ESI): m/z calcd for C28H30N4O7+Na+: 557.2012 [M+Na]+; found 
557.2007. 
Ç-Bz-DMT (6). Ç-Bz (16 mg, 0.03 mmol), DMTCl (21 mg, 0.06 
mmol) and DMAP (0.8 mg, 0.01 mmol) were added to a round-
bottomed flask and dried in vacuo for 16 h. Pyridine (2 mL) was 
added and the solution stirred for 16 h, after which MeOH (0.50 
mL) was added and the solvent removed in vacuo. The residue 
was purified by flash column chromatography using a gradient 
elution (MeOH:CH2Cl2:Et3N, 0:99:1 to 95:4:1), to yield 6 (20 mg, 
95%) as a yellow solid. 1H NMR (400 MHz, CDCl3): δ = 8.18 – 
8.09 (m, 3H), 7.64 – 7.56 (m, 2H), 7.49 (d, J = 7.8 Hz, 4H), 7.40 
(d, J = 8.2 Hz, 4H), 7.31 (t, J = 7.6 Hz, 2H), 7.20 (t, J = 7.3 Hz, 
1H), 6.86 (dd, J = 8.7, 3.8 Hz, 4H), 6.52 – 6.46 (m, 1H), 6.43 (s, 
1H), 6.25 (s, 1H), 4.70 – 4.56 (m, 1H), 4.15 (dd, J = 8.8, 5.2 Hz, 
1H), 3.75 (d, J = 6.6 Hz, 6H), 3.41 (ddd, J = 26.5, 10.7, 3.2 Hz, 
2H), 2.71 (d, J = 12.8 Hz, 1H), 2.37 – 2.21 (m, 1H), 1.48 ppm (d, 
J = 12.2 Hz, 12H); 13C NMR (101 MHz, CDCl3): δ = 166.21, 159.56, 
154.79, 154.60, 148.34, 144.57, 142.44, 139.75, 139.32, 136.66, 
133.17, 130.10, 130.05, 129.60, 129.38, 128.60, 128.15, 128.14, 
128.05, 127.97, 126.91, 126.30, 122.05, 113.27, 108.58, 106.64, 
86.88, 86.33, 86.26, 71.33, 68.65, 68.54, 63.40, 60.42, 55.21, 
41.79, 39.06, 29.37, 28.87, 25.44, 21.07, 14.22 ppm; HRMS 
(ESI): m/z calcd for C49H48N4O9+Na+: 859.3319 [M+Na]+; found 
859.3313. 
Ç-Bz phosphoramidite (3). A solution of compound 6 (21 mg, 
0.02 mmol) in CH2Cl2 (1 mL) was treated with diisopropyl 
ammonium tetrazolide (5 mg, 0.03 mmol) and 2-cyanoethyl 
N,N,N’,N’-tetraisopropylphosphane (11 µL, 0.03 mmol). The 
resulting solution was stirred at 22 °C for 2 h. CH2Cl2 (50 mL) was 
added and the solution washed with satd. aq. NaHCO3 (3 × 50 
mL) and brine (50 mL), dried over Na2SO4 and concentrated in 
vacuo. The residue was dissolved in a minimum amount of CH2Cl2 
(few drops), followed by slow addition of n-hexane (40-50 mL) at 
22 °C. The solvent was decanted from the precipitate and 
discarded. This procedure was repeated four times to give 3 (20 
mg, 80%) as a yellowish solid. 1H NMR (400 MHz, CDCl3): δ = 
8.06-8.04 (m, 2H), 7.53 (s, 1H), 7.46 – 7.34 (m, 6H), 7.32-7.24 (m, 
6H), 7.16 (dd, J = 7.4, 4.0 Hz, 1H), 6.79 (dq, J = 6.3, 2.2 Hz, 4H), 
6.30 – 6.19 (m, 1H), 6.17 (d, J = 8.2 Hz, 1H), 4.58 (d, J = 14.0 Hz, 
1H), 4.08 (t, J = 3.8 Hz, 1H), 3.69 (dd, J = 5.3, 2.1 Hz, 6H), 3.61 
– 3.25 (m, 6H), 2.52 (q, J = 10.7, 8.4 Hz, 2H), 2.38 (t, J = 6.4 Hz, 
1H), 2.22 (d, J = 11.4 Hz, 1H), 1.41 (t, J = 11.0 Hz, 12H), 1.13 – 
0.97 (m, 12H) ppm; 13C NMR (101 MHz, CDCl3): δ = 158.61, 
144.36, 139.29, 133.10, 130.18, 130.13, 130.10, 129.62, 129.47, 
128.56, 128.26, 127.96, 126.99, 113.28, 113.25, 108.46, 86.88, 
85.76, 77.22, 68.66, 68.59, 62.60, 58.36, 58.16, 55.24, 55.21, 
43.38, 43.26, 43.20, 40.45, 31.59, 25.49, 24.65, 24.58, 24.51, 
22.66, 20.25, 20.18, 14.12 ppm; 31P NMR (162 MHz, CDCl3): δ = 
149.25, 148.63 ppm.  
TBDMS-Çm (2). To a solution of Çm[26] (290 mg, 0.63 mmol) in 
DMF (6 mL) and pyridine (1.5 mL) were added TBDMSCl (286 
mg, 1.89 mmol) and imidazole (129 mg, 1.89 mmol). The resulting 
solution was stirred at 22 °C for 16 h. H2O (50 mL) and EtOAc (20 
mL) were added, the organic phase separated and washed with 
satd. aq. NaHCO3 (5 x 50 mL). The organic phase was dried over 
Na2SO4, concentrated in vacuo and purified by flash column 
chromatography using a gradient elution (MeOH:CH2Cl2; 0:100 to 
10:90), yielding 2 (299 mg, 81%) as a yellow solid. HRMS (ESI): 






m/z calcd for C34H55N4O7Si2+Na+: 710.3501 [M+Na]+; found 
710.3500. 
TBDMS-Çm-Bz (7). To a solution of 2 (235 mg, 0.34 mmol) in 1,4-
dioxane (30 mL) was added L-ascorbic acid (301 mg, 1.71 mmol) 
in H2O (5 mL). The reaction mixture was stirred at 40 °C for 1 h, 
after which CH2Cl2 (30 mL) and H2O (30 mL) were added and the 
solution was stirred vigorously for 2 min. The organic phase was 
separated and filtered through a short pad of Na2SO4, in a 
dropping funnel under an inert atmosphere of Ar, into a solution 
of BzCl (198 μL, 0.34 mmol), Et3N (953 μL, 6.83 mmol) in CH2Cl2 
(10 mL). The solution was stirred at 22 °C for 2 h, washed with 
satd. aq. NaHCO3 (3 x 100 mL), the organic phase dried over 
Na2SO4, concentrated in vacuo and the residue purified by flash 
column chromatography using a gradient elution (MeOH:CH2Cl2; 
0:100 to 10:90), to yield 7 (269 mg, quant.) as a yellow solid. 1H 
NMR (400 MHz, CDCl3): δ = 8.14 (s, 2H), 7.81 (s, 1H), 7.59 (t, J 
= 7.5 Hz, 1H), 7.49 (s, 1H), 7.51 – 7.44 (m, 2H), 6.41 (s, 1H), 5.88 
(s, 1H), 4.22 (dt, J = 8.7, 4.3 Hz, 1H), 4.14 – 4.02 (m, 2H), 3.81 
(dd, J = 11.9, 1.8 Hz, 1H), 3.68 (d, J = 4.6 Hz, 1H), 3.64 (s, 3H), 
1.49 (s, 12H), 1.02 (s, 9H), 0.90 (s, 9H), 0.22 (dd, J = 7.5, 2.4 Hz, 
6H), 0.09 ppm (dd, J = 5.9, 2.4 Hz, 6H); 13C NMR (101 MHz, 
CDCl3): δ = 171.21, 166.14, 160.84, 155.20, 153.56, 142.62, 
140.04, 139.53, 133.19, 133.15, 130.29, 130.16, 129.63, 129.44, 
129.03, 128.58, 128.29, 127.69, 126.27, 122.06, 111.93, 108.14, 
88.08, 87.47, 84.14, 83.11, 68.71, 68.63, 68.61, 68.52, 68.03, 
62.97, 61.64, 60.51, 57.98, 28.93, 26.37, 26.34, 25.82, 25.76, 
25.49, 18.78, 18.73, 18.15, 18.10, -4.45, -4.50, -4.83, -5.11, -5.20, 
-5.29, -5.34 ppm; HRMS (ESI): m/z calcd for C41H60N4O8Si2+Na+: 
815.3842 [M+Na]+; found 815.3853. 
Çm-Bz. To a solution of 7 (271 mg, 0.34 mmol) in THF (18 mL) 
was added TBAF (1.2 mL, 1.20 mmol, 1.0 M in THF) and the 
reaction stirred at 22 °C for 18 h. The reaction was concentrated 
in vacuo and the residue purified by flash column chromatography 
using a gradient elution (MeOH:CH2Cl2; 0:100-10:90), to yield 
Çm-Bz (139 mg, 72%) as a yellow solid. 1H NMR (400 MHz, 
CDCl3): δ = 8.11 (td, J = 7.3, 6.6, 1.4 Hz, 2H), 7.59 (td, J = 7.4, 
3.6 Hz, 1H), 7.57 – 7.51 (m, 1H), 7.45 (dt, J = 18.4, 7.7 Hz, 2H), 
6.45 (d, J = 18.7 Hz, 1H), 5.72 – 5.67 (m, 1H), 4.95 (s, 1H), 4.38 
(t, J = 4.8 Hz, 1H), 4.31 (dt, J = 9.1, 4.8 Hz, 1H), 4.00 (d, J = 6.5 
Hz, 2H), 3.89 (q, J = 5.4 Hz, 1H), 3.62 (d, J = 3.9 Hz, 3H), 1.51 – 
1.24 ppm (m, 12H); 13C NMR (101 MHz, CDCl3): δ = 170.91, 
166.35, 160.98, 154.87, 153.61, 142.50, 142.19, 141.16, 140.16, 
139.44, 133.30, 130.12, 129.62, 129.23, 128.62, 128.36, 128.03, 
127.93, 125.91, 125.39, 123.08, 111.54, 108.77, 100.90, 89.88, 
84.49, 82.98, 77.39, 77.28, 77.08, 76.76, 68.61, 68.56, 68.11, 
67.31, 67.26, 66.55, 63.66, 62.97, 60.69, 58.53, 53.46, 29.26, 
28.77, 25.41, 24.99 ppm; HRMS (ESI): m/z calcd for 
C29H32N4O8+Na+: 587.2112 [M+Na]+; found 587.2096. 
Çm-Bz-DMT (8). Toluene (3 x 5 mL) was evaporated from Çm-
Bz (139 mg, 0.25 mmol), followed by sequential addition of 
pyridine (4 mL), DMTCl (834 mg, 2.46 mmol) and DMAP (6 mg, 
0.05 mmol). The solution was stirred for 14 h, MeOH (400 μL) was 
added and the solvent removed in vacuo. The residue was 
purified by flash column chromatography using a gradient elution 
(MeOH:CH2Cl2:Et3N; 0:99:1 to 1:98:1), to yield 8 (87 mg, 41%) as 
a yellow solid. 1H NMR (400 MHz, CDCl3): δ = 8.13 (d, J = 7.2 
Hz), 7.72 (s, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.51-7.50 (m, 2H), 7.49-
7.48 (m, 2H), 7.43-7.40 (m, 4H), 7.33-7.31 (m, 2H), 7.22-7.18 (m, 
1H), 6.88 (s, 1H), 6.88-6.85 (m, 4H), 6.11 (s, 1H), 5.87 (s, 1H), 
4.55-4.52 (m, 1H), 4.02 (d, J = 8.6 Hz, 1H), 3.93 (bs, 1H), 3.75 (s, 
6H), 3.73 (s, 3H), 3.60-3.49 (m, 2H), 1.51 ppm (d, J = 25.2 Hz, 
12H); 13C NMR (101 MHz, CDCl3): δ = 166.15, 158.57, 155.18, 
153.79, 142.30, 139.88, 139.26, 135.57, 133.13, 130.09, 129.62, 
129.47, 128.57, 128.23, 128.01, 127.84, 126.92, 125.98, 121.80, 
113.36, 113.31, 111.78, 108.71, 87.87, 86.82, 83.77, 82.91, 68.70, 
68.61, 68.19, 60.84, 58.56, 55.21, 45.82, 29.72, 25.47 ppm; 
HRMS (ESI): m/z calcd for C50H50N4O10+Na+: 889.3419 [M+Na]+; 
found 889.3395. 
Çm-Bz phosphoramidite (4). A solution of 8 (20 mg, 0.02 mmol) 
in CH2Cl2 (1 mL) was treated with diisopropyl ammonium 
tetrazolide (6 mg, 0.04 mmol) and 2-cyanoethyl N,N,N’,N’-
tetraisopropylphosphane (22 μL, 0.07 mmol). The reaction was 
stirred at 22 °C for 18 h. CH2Cl2 (15 mL) was added and the 
solution washed with satd. aq. NaHCO3 (3 x 30 mL), dried over 
Na2SO4 and concentrated in vacuo. The residue was dissolved in 
Et2O (2 mL) followed by slow addition of n-hexane (10 mL). The 
solvent was decanted from the precipitate and discarded. This 
procedure was repeated six times to yield 4 (18 mg, 71%) as a 
yellow solid. 1H NMR (400 MHz, CDCl3): δ = 8.12 (dd, J = 8.3, 1.4 
Hz, 4H), 7.64 – 7.57 (m, 3H), 7.53 – 7.44 (m, 10H), 7.44 – 7.34 
(m, 11H), 7.31 (td, J = 7.8, 2.1 Hz, 6H), 7.22 (tt, J = 7.4, 1.9 Hz, 
3H), 6.86 (ddt, J = 8.7, 5.9, 3.4 Hz, 10H), 6.14 (d, J = 15.5 Hz, 
1H), 6.06 (d, J = 7.6 Hz, 1H), 5.97 (s, 1H), 4.29 (tt, J = 5.0, 2.6 Hz, 
1H), 4.25 – 4.20 (m, 2H), 3.98 (q, J = 7.0, 6.4 Hz, 2H), 3.77 – 3.73 
(m, 13H), 3.65 (dd, J = 4.0, 1.2 Hz, 6H), 2.46 – 2.38 (m, 2H), 1.55 
– 1.38 (m, 28H), 1.26 (ddt, J = 5.7, 3.6, 2.2 Hz, 15H), 1.22 – 1.18 
(m, 11H), 1.18 – 1.03 (m, 15H), 0.92 – 0.84 ppm (m, 8H); 13C NMR 
(101 MHz, CDCl3): δ = 165.92, 158.38, 155.03, 153.66, 142.02, 
132.86, 130.10, 129.37, 128.32, 127.69, 126.77, 125.79, 121.65, 
117.33, 113.00, 111.78, 108.29, 88.35, 86.49, 77.16, 68.45, 54.98, 
43.16, 24.51, 20.10 ppm; 31P NMR (162 MHz, CDCl3): δ = 150.52, 
150.08 ppm; HRMS (ESI): m/z calcd for C50H60N4O10+Na+: 
1089.4498 [M+Na]+; found 1089.4498. 
DNA and RNA syntheses, purification and characterization. 
All commercial phosphoramidites, CPG columns and solutions for 
oligonucleotide syntheses were purchased from ChemGenes 
Corp., USA. DNA and RNA solid-phase oligonucleotide 
syntheses were performed on an automated ASM800 DNA/RNA 
synthesizer (BIOSSET Ltd., Russia) using phosphoramidite 
chemistry. Unmodified and spin-labeled oligonucleotides were 
synthesized using a trityl-off protocol and phosphoramidites with 
standard protecting groups on 1 μmol scale (1000 Å CPG 
columns). Oxidation was performed with tert-butylhydroperoxide 
in toluene (1.0 M). Capping and detritylation were performed 
under standard conditions for DNA and RNA oligonucleotide 
synthesis.  
The Ç-modified DNAs were synthesized using phosphoramidite 3. 
Unmodified phosphoramidites were dissolved in CH3CN (100 
mM) and 3 was dissolved in 1,2-dichloroethane (100 mM). 5-
Ethylthiotetrazole (250 mM) was used as a coupling agent and 
the coupling time was set to 1.5 min for unmodified 
phosphoramidites and to 5 min for the Ç-modified 
phosphoramidites. The DNAs were deprotected in satd. aqueous 
NH3 at 55 °C for 8 h and dried in vacuo.  






For the RNA synthesis, 2’O-TBDMS protected ribonucleoside 
phosphoramidites were used and dissolved in CH3CN (100 mM). 
The Çm-modified RNAs were synthesized using phosphoramidite 
4, dissolved in 1,2-dichloroethane (100 mM). 5-Ethylthiotetrazole 
(250 mM) was used as a coupling agent for phosphoramidite 4, 
5-benzylthiotetrazole (250 mM) was used as a coupling agent for 
unmodified phosphoramidites and the coupling time was set to 7 
min. The RNAs were deprotected and cleaved from the resin by 
adding a 1:1 solution (2 mL) of CH3NH2 (8 M in EtOH) and NH3 
(satd. in H2O) and heating at 65 °C for 1 h. The solvent was 
removed in vacuo and the 2’O-TBDMS groups were removed by 
incubation in Et3N·3HF (300 μL) in DMF (100 μL) at 55 °C for 1.5 
h, followed by addition of deionized and sterilized water (100 μL). 
This mixture was transferred to a 50 mL Falcon tube and n-
butanol (20 mL) was added and stored at −20 °C for 14 h, 
centrifuged and the solvent decanted from the RNA pellet.  
All oligonucleotides were subsequently purified by 20% DPAGE 
and extracted from the gel slices using the “crush and soak 
method” with Tris buffer (250 mM NaCl, 10 mM Tris, 1 mM 
Na2EDTA, pH 7.5). The solutions were filtered through GD/X 
syringe filters (0.45 μm, 25 mm diameter, Whatman, USA) and 
were subsequently desalted using Sep-Pak cartridges (Waters, 
USA), following the instructions provided by the manufacturer. 
Dried oligonucleotides were dissolved in deionized and sterilized 
water (200 μL for each oligonucleotide). Concentrations of the 
oligonucleotides were determined by measuring absorbance at 
260 nm using a Perkin Elmer Inc. Lambda 25 UV/VIS 
spectrometer and calculated by Beer′s law. Mass spectrometric 
analyses of Ç- and Çm-labeled oligonucleotides were performed 
on an HRMS (ESI) (Bruker, MicrOTOF-Q) in negative ion mode.  
Enzymatic digestion of DNA and RNA and HPLC analysis. To 
the oligonucleotide (4 nmol) in sterile water (8 μL) was added calf 
intestinal alkaline phosphatase (1 μL, 2 U), snake venom 
phosphodiesterase I (4 μL, 0.2 U), nuclease P1 from penicillium 
citrinum (5 μL, 1.5 U) and Tris buffer (2 μL, 500 mM Tris and 100 
mM MgCl2). The samples were incubated at 37 °C for 50 h. 
Enzymatically digested oligonucleotides were run on a Beckman 
Coulter Gold HPLC system using Beckman Coulter Ultrasphere 
C18 4.6 x 250 mm analytical column with UV detection at 254 nm. 
Solvent gradients for analytical RP-HPLC were run at 1.0 mL/min 
using following gradient program: solvent A, TEAA buffer (50 mM, 
pH 7.0); solvent B, CH3CN; 0-4 min isocratic 4% B, 4-14 min linear 
gradient 4-20% B, 14-24 min linear gradient 20-50% B, 24-29 min 
linear gradient 50-80% B, for 29-30 min isocratic 80% B, 30-35 
min linear gradient 80-4% B and 35-45 min isocratic 4% B. 
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Protect your spin labels: During 
chemical synthesis of nitroxide spin-
labeled oligonucleotides by the 
phosphoramidite approach, the 
nitroxide is partially reduced to the 
corresponding amine. This side-
reaction can be circumvented by 
utilizing a benzoylated hydroxylamine 
as a protected form of the nitroxide. 
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